Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Genprex, inc. symbols : AZN save search
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.17%
H: 0.09%
C: -2.76%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 33.84%
H: 1.01%
C: -15.3%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.76%
H: 0.77%
C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.34%
H: 0.21%
C: -2.03%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 1.12%
H: 2.16%
C: -10.76%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.44%
H: 0.03%
C: -1.94%
reqorsa lung approval review cancer cell expansion trial
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: -0.02%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 3.65%
H: 7.04%
C: 1.02%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.06%
H: 0.48%
C: -0.04%
reqorsa lung asco positive cancer cell meeting trial therapy
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -1.61%
H: 1.82%
C: 1.82%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 2.34%
H: 5.98%
C: -0.85%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.76%
H: 1.04%
C: 0.47%
reqorsa lung trial approval review cancer
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
Published: 2022-08-15 (Crawled : 12:20) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -0.09%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 7.91%
H: 13.09%
C: 9.42%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
tagrisso lung trial review cancer phase 1
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 3.95%
H: 5.06%
C: -7.17%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
tagrisso gene therapy trial cel lung cancer phase 1 therapy cancer
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.